2019;140:e125 2019 by the American Heart Association, Inc., the American College of Cardiology Foundation, and the Heart Rhythm Society. ACC/AHA/HRS GUIDELINE 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Circulation https://www.ahajournals.org/journal/circ ACC/AHA Task Force Members, see page e142 Key Words: AHA Scientific Statements focused update acute coronary syndrome anticoagulants anticoagulation agents antiplatelet agents apixaban atrial fibrillation atrial flutter cardioversion coronary artery disease coronary heart disease stents dabigatran edoxaban hypertension idarucizumab myocardial infarction obesity percutaneous coronary intervention risk factors rivaroxaban sleep apnea stroke thromboembolism warfarin WRITING GROUP MEMBERS* Craig T. January, MD, PhD, FACC, Chair L. Samuel Wann, MD, MACC, FAHA, Vice Chair Hugh Calkins, MD, FACC, FAHA, FHRS* Lin Y. Chen, MD, MS, FACC, FAHA, FHRS Joaquin E. Cigarroa, MD, FACC Joseph C. Cleveland Jr, MD, FACC* Patrick T. Ellinor, MD, PhD* Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA* Michael E. Field, MD, FACC, FAHA, FHRS Karen L. Furie, MD, MPH, FAHA Paul A. Heidenreich, MD, FACC, FAHA Katherine T. Murray, MD, FACC, FAHA, FHRS Julie B. Shea, MS, RNCS, FHRS* Cynthia M. Tracy, MD, FAHA Clyde W. Yancy, MD, MACC, FAHA Developed in Collaboration With the Society of Thoracic Surgeons CLINICAL STATEMENTS AND GUIDELINES TABLE OF CONTENTS Preamble (Full Version) e126 1. Introduction e128 1.1. Methodology and Evidence Review e129 1.2. Organization of the Writing Group e129 1.3. Document Review and Approval e129 1.4. Abbreviations e129 4. Prevention of Thromboembolism e130 4.1. Risk-Based Anticoagulant Therapy (Modified From Section 4.1., Risk-Based Antithrombotic Therapy, in the 2014 AF Guideline) e130 4.1.1. 